Shire: Why Analysts Expect Revenue Growth in Q3 2018

Shire’s revenues

Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1. The expectation is ~$3.82 billion compared to ~$3.7 billion for the third quarter of 2017.

Shire: Why Analysts Expect Revenue Growth in Q3 2018

The above chart compares the revenues for Shire since the first quarter of 2017.

Revenues estimates for Q3

Analysts expect third-quarter revenue growth to be driven by strong product sales, partially impacted by lower royalty revenues and other revenues.

Products in immunology, hematology, and neuroscience are expected to have positive growth YoY (year-over-year). Generic diseases, internal medicines, ophthalmic products, and oncology are also expected to see YoY growth. Established brands, however, could see a decline in revenues.

The Invesco International Dividend Achievers ETF (PID) holds 0.3% of its total investments in Shire (SHPG), 2% in Novartis (NVS), 2.3% in Sanofi (SNY), and 0.5% in Fresenius Medical Care (FMS).